

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTC

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	1	of	2
-------	---	----	---

Complete if Known

Application Number	10/621,684
Filing Date	July 17, 2003
First Named Inventor	Scott A. Waldman
Art Unit	1639
Examiner Name	Sue Xu Liu
Attorney Docket Number	100051.10171

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date/Filing Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	† ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
	5	JP 63-501876 (w/Eng. abstract from corr. EP 0271180)	07-28-1998	Dow Chemical		
	6	JP 04-503945 (w/Eng. abstract from corr. WO 90/03801)	07-16-1992	Univ of So. California		
	7	JP 06-503347 (w/Eng. abstract from corr. WO 92/11037)	04-14-1994	Advanced Magnetics		
	8	JP 06-511466 (w/Eng. abstract from corr. WO 93/02709)	12-22-1994	Microcarb		
	9	JP 04-503307 (w/Eng. abstract from corr. to WO 90/09197)	06-18-1992	Oncogen		
		WO 93/02708	02-18-1993	Antisoma		

Examiner Signature	Date Considered
-----------------------	--------------------

EXAMINER. Include if reference considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Initial copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). * See Kind Codes of the USPTO Patent Documents at www.uspto.gov or MPEP § 901.04. * Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). * For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. * Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. * Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTD-9199 and select option 2.

Substitute for form 1448B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 2 of 2

Complete if Known

Application Number 10/621,684
Filing Date July 17, 2003
First Named Inventor Scott A. Waldman
Art Unit 1639
Examiner Name Sue Xu Liu
Attorney Docket Number 100051.10171

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	10	Eildon "Cytotoxicity and viability assays," Animal Cell Culture: A Practical Approach, Freshney, R.I. (Ed.), IRL Press, Oxford, pages 183-216 (1986).	
	11	Drewett et al., "The family of guanylyl cyclase receptors and their ligands," Endocrine Reviews (1994) 15(2):135-162.	
	12	Waldman et al., "Influence of a glycine or proline substitution on the functional properties of a 14-amino-acid analog of Escherichia coli heat-stable enterotoxin," Infection and Immunity (1989) 57:2420-2424.	
	13	White et al., "Opossum kidney contains a functional receptor for the escherichia coli heat-stable enterotoxin," Biochemical and Biophysical Res Comm (1989) 159(1):363-357.	
	14	Shimonishi et al., "Mode of disulfide bond formation of a heat-stable enterotoxin (STn) produced by a human strain of enterotoxigenic Escherichia coli," Elsevier Science (1987) 215(1):165-170.	

Examiner Signature	Date Considered
-----------------------	--------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.